• Differentiate the key inflammatory endotypes (Type 2 vs. non–Type 2) of chronic rhinosinusitis (CRS) and their underlying immunopathology. 
• Apply current classification schemes (e.g., European Position Paper [EPOS] vs. JESREC) to stratify CRS patients for tailored management. 

• Select and optimize treatments regimens based on CRS phenotype and severity.
• Incorporate advanced topical delivery techniques and novel medical options including biologic agents into practice.

By the end of this session, participants will be able to

• Develop a standardized preoperative protocol (medical optimization, imaging review, anesthesia considerations) to minimize intraoperative risk.
• Implement evidence-based postoperative care pathways (saline irrigations, topical steroids, debridements) to enhance mucosal healing and outcomes.

By the end of this session, participants will be able to:

• Describe the “Full-House” FESS framework, including techniques for maxillary antrostomy, ethmoidectomy, sphenoidotomy, and frontal sinusotomy.
• Identify patient- and disease-specific factors that guide decision-making for comprehensive versus targeted FESS.

By the end of this session, participants will be able to

• Correlate high-resolution CT/MRI landmarks with endoscopic anatomy, emphasizing danger zones (skull base, lamina papyracea) and frontal sinus drainage pathways.
• Identify high-risk anatomical variants (Onodi cells, Haller cells, concha bullosa) that impact surgical planning and risk.

By the end of this session, participants will be able to

• Employ advanced hemostatic strategies to maintain a clear field.
• Discuss preoperative and intraoperative measures to optimize operating conditions.
• Adjust endoscope positioning and OR setup to reduce surgeon fatigue and enhance precision.

By the end of this session, participants will be able to

• Compare endoscopic frontal recess surgical techniques and recognize indications for the Modified Lothrop  procedure.
• Execute stepwise surgical landmarks and maneuvers for safe frontal sinusotomy, minimizing risk of complications and optimizing chances of success.

By the end of this session, participants will be able to

• Analyze causes of surgical failure and plan targeted revision strategies.
• Integrate adjunctive therapies (biologics, topical antifungals, stenting) into the management of recalcitrant cases.

By the end of this session, participants will be able to

• Review the relevant nasal anatomy
• Describe the indications for endoscopic septoplasty, including transseptal approaches to the sella turcica and for choanal atresia repair
• Outline endoscopic approaches for septoplasty and transseptal access, highlighting technical tips for successful endoscopic septoplasty

By the end of this session, participants will be able to

• Identify endoscopic corridors and key landmarks for medial orbital decompression, and access for well-selected orbital apex lesion and middle cranial fossa.
• Anticipate and manage orbital-specific complications (orbital hemorrhage, extraocular muscle injury).

By the end of this session, participants will be able to

• Recognize serious intraoperative complications (CSF leak, orbital injury, hemorrhage) and institute immediate management steps.
• Implement protocols for intraoperative care and postoperative monitoring to reduce morbidity.

By the end of this session, participants will be able to

• Differentiate patterns of olfactory loss in post-viral (including COVID-19) vs. inflammatory CRS etiologies.
• Counsel patients on evidence-based interventions (steroid irrigation, olfactory training) and set realistic recovery expectations.

By the end of this session, participants will be able to

• Apply current indications and contraindications for anti-IL-5, anti-IL-4Rα, and anti-IgE therapies in CRS with nasal polyposis.
• Develop individualized treatment algorithms that integrate surgery, topical therapies, and biologics for optimized long-term disease control.